Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $26.1252W HIGH $37.51
Volume
476.97 K
Value Traded
32.73 M
Short % Float
1.16%
+2.4%Week
-2.68%1 Month
-11.87%3 Month
-19.19%6 Month
-30.66%5 Year
+278.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.33 B
EPS (TTM)
1.44
P/E Ratio
18.72
Ent. Value
15.77 B
Total Shares
418.52 M
Float Shares
418.28 M
Insiders
0.06%
Institutions
13.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SNN Catalyst Timeline
Dated clinical, regulatory and corporate events for Smith & Nephew SNATS, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Smith & Nephew SNATS, Inc.
34Total events
7Upcoming
3Tier-1 (high impact)
2025 to 2027Coverage
Upcoming catalysts 2
Event history 23
●Oral PresentationPresentation
CARTIHEAL Implant featured at ICRS Summit in Porto, Portugal
cartilage repairsource ↗
●Oral PresentationPresentation
CARTIHEAL AGILI-C to be presented at ICRS Summit in Porto, Portugal
cartilage repairsource ↗
▲Product LaunchPost-Market
CARTIHEAL AGILI-C Cartilage Repair Implant commercially available in Europe
cartilage repairsource ↗
▲Product LaunchPost-Market
CARTIHEAL AGILI-C Cartilage Repair Implant now commercially available in Europe
cartilage repairsource ↗
▲Product LaunchPost-Market
Smith+Nephew launches EVOS PELVIC Plating System in the United States
pelvic and acetabular fracturessource ↗
●R&D DayPresentation
EVOS PELVIC System available for surgeon preview at 2026 OTA Annual Meeting, Nashville
pelvic and acetabular fracturessource ↗
▲Product LaunchPost-Market
Q-FIX KNOTLESS 2.8 All-Suture Anchor launching at ICSES 2026
shoulder repair and reconstructionsource ↗
●Oral PresentationPresentation
Smith+Nephew showcase of shoulder technologies at ICSES 2026
rotator cuff repairsource ↗
▲FDA ApprovalFDA Decision
FDA 510(k) clearance of LANDMARK Total Knee System
total knee arthroplastysource ↗
▲First Patient DosedTrial
First surgical cases completed with LANDMARK Total Knee System
total knee arthroplastysource ↗
●Debt Royalty FinancingCorporate
Intention to issue senior notes due 2036 in Concurrent Notes Offering
▲First Patient DosedTrial
First surgical cases completed with LANDMARK Total Knee System
total knee arthroplastysource ↗
▲FDA ApprovalFDA Decision
FDA grants De Novo classification to TESSA Spatial Surgery System
femoral anterior cruciate ligament reconstruction (ACLR) surgery of the kneesource ↗
▲Product LaunchPost-Market
Commercial launch of LYNX COBLATION Laryngeal Wand
airway proceduressource ↗
▲Product LaunchPost-Market
Commercial introduction of TESSA Spatial Surgery System expected in Q3 2026
femoral anterior cruciate ligament reconstruction (ACLR) surgery of the kneesource ↗
▲PublicationPresentation
Study published showing early recovery time halved with REGENETEN vs suture anchor repair
partial thickness rotator cuff tearssource ↗
▲Product LaunchPost-Market
Phased commercial introduction of LANDMARK Knee
total knee arthroplastysource ↗
▲Long Term DataClinical Data
5-year follow-up data showing superiority vs surgical standard of care
knee cartilage defectssource ↗
▲PublicationPresentation
Five-year follow-up RCT results for CARTIHEAL AGILI-C published in American Journal of Sports Medicine
knee chondral and osteochondral lesionssource ↗
▲PublicationPresentation
Five-year follow-up RCT results published in American Journal of Sports Medicine
knee chondral and osteochondral lesionssource ↗
●PublicationPresentation
Novel Tendon-to-Bone Seam Technique for Rotator Cuff Repair presentation at OSET
rotator cuff repairsource ↗
Past FDA Catalysts and PDUFA Decisions
How SNN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2018-12-05 | Regranex (becaplermin) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Smith & Nephew SNATS, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SNN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| REGENETEN Bioinductive Implant | partial-thickness rotator cuff tears | 2026-04-09 | early recovery time was halved; Driving: 2.3 vs 5.1 weeks (p<0.001); Office work: 1.7 vs 3.6 weeks (p=0.009); Moderate-intensity household chores: 3.8 vs 8.4 weeks (p<0.001)Read More | Smith+Nephew’s REGENETEN◊ Bioinductive Implant shows post-operative recovery times halved, and high healing rates for partial-thickness rotator cuff tears1,*Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.4 % (-6.7 %) | 12.83 M | 470.20 K | -28.09% ( -183.70 K) |
SNN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNN ranks across every disease it competes in
Competitive Position is a premium feature
See how SNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNN News
SNN▲ +0.5%today
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
Smith+Nephew has announced the European launch of its innovative cartilage repair implant, CARTIHEAL AGILI-C, which will be presented at the ICRS Summit in Portugal. The implant, made from aragonite, promotes cartilage and bone regeneration and has shown superior clinical outcomes compared to standard surgical care. Patients reported significant pain relief and improved functional outcomes over a five-year follow-up period.
Read more →SNN▲ +0.5%today
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew has launched its CARTIHEAL AGILI-C Cartilage Repair Implant in Europe, which will be featured at the ICRS Summit in Porto. The implant, made from aragonite, has shown clinical superiority in trials, offering better pain relief and functional improvements for patients with cartilage damage. This launch aims to expand access to advanced treatment options for orthopedic conditions.
Read more →SNNSmith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew has launched the EVOS PELVIC Plating System at the 2026 OTA Annual Meeting. This all-in-one system combines plates, screws, and specialized tools to enhance pelvic and acetabular fracture management. The system aims to streamline complex surgeries and improve outcomes for patients of varying ages and bone quality.
Read more →SNNNatural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
Smith+Nephew has received FDA 510(k) clearance for its LANDMARK Total Knee System, designed to replicate healthy knee anatomy. The first surgical cases have been completed, demonstrating the system's potential for personalized knee replacement solutions. The launch will be phased, with broader availability expected by 2027. The system will be showcased at the upcoming AAHKS Annual Meeting.
Read more →SNNSmith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew will present its advanced shoulder repair technologies at the ICSES 2026 in Vancouver from September 22-25. Key highlights include the TENDON SEAM Rotator Cuff Repair System, REGENETEN Bioinductive Implant, and the Q-FIX KNOTLESS All-Suture Anchor. These innovations aim to improve surgical outcomes and patient recovery times, showcasing the company's commitment to enhancing joint repair procedures.
Read more →SNNSmith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc has successfully completed a cash tender offer for up to $250 million of its 2.032% Senior Notes due 2030. The offer, which expired on September 15, 2026, saw a total of $431.8 million in notes tendered, exceeding the maximum amount. Due to the high participation, proration will be applied to the accepted notes, with settlement expected on September 18, 2026.
Read more →SNNSmith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc has announced the pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030. The tender offer is set to expire on September 15, 2026, unless extended. Holders of the notes are advised to review the Offer to Purchase for detailed participation procedures. The company anticipates announcing the results shortly after the expiration.
Read more →SNNSmith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith & Nephew Plc has announced a cash tender offer to purchase up to $250 million of its 2.032% Senior Notes due 2030. This initiative aims to manage the company's debt portfolio effectively and extend the maturity profile of its existing obligations. The tender offer is contingent upon the successful completion of a concurrent notes offering, which is expected to take place shortly.
Read more →SNNSmith+Nephew and Imperial College London launch centre to accelerate innovation in surgical robotics
Smith+Nephew and Imperial College London have launched a five-year partnership to enhance robotic surgery for musculoskeletal conditions. This collaboration aims to translate academic research into practical applications, making robotic techniques less invasive and more widely available. The center will focus on innovative technologies such as markerless tracking and real-time computer vision.
Read more →SNNSmith+Nephew’s new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options
Smith+Nephew has launched the FLOW FLEXTEND COBLATION Wand, enhancing RF resection technology for hip procedures. This device features an adjustable-angle tip for improved access and precision in complex surgeries. Surgeons have reported positive feedback on its versatility and effectiveness compared to existing options. The wand utilizes proprietary COBLATION Technology, which has been clinically proven to improve patient outcomes.
Read more →SNNSmith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week
Smith+Nephew is participating in the 2026 Pro Football Hall of Fame Enshrinement Week, showcasing its commitment to movement and recovery. The company will host interactive activities, including meet-and-greets with Hall of Famers and live podcasts. This event emphasizes the connection between sports and health, aligning with Smith+Nephew's mission of 'Life Unlimited'.
Read more →SNNSmith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation
Smith+Nephew has received De Novo classification from the FDA for its TESSA Spatial Surgery System, marking a significant advancement in sports medicine. This system utilizes AI and augmented reality to enhance surgical precision in ACL reconstruction. The TESSA System is expected to be commercially available in Q3 2026, with broader applications anticipated in the future.
Read more →SNNSmith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
Smith+Nephew has launched ASC Solutions, an enterprise strategy aimed at enhancing ambulatory surgery centers (ASCs) by focusing on cost optimization and quality outcomes. The ASC ONE delivery model integrates various services to streamline operations and improve patient care. This initiative is designed to support healthcare providers in navigating a complex value-based care environment.
Read more →SNNFormer Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner
Craig Gaffin, former president of Smith+Nephew's global orthopaedics division, has joined MedEdge Holdings as a partner. His role will involve identifying acquisition opportunities and supporting growth within MedEdge's portfolio of surgical technology companies. MedEdge aims to enhance the commercialization of innovative surgical products by leveraging its extensive network and expertise.
Read more →SNNSmith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons
Smith+Nephew has launched the LYNX COBLATION Laryngeal Wand, designed for ENT procedures. This innovative device features a long working length and self-clearing capabilities, enhancing surgical efficiency. Surgeons have provided positive feedback regarding its versatility and effectiveness in tissue removal. The wand utilizes patented COBLATION technology, ensuring precise tissue management.
Read more →SNNNew German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
Smith+Nephew has announced the publication of new expert consensus guidelines for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions in Germany. This guidance aims to reduce post-surgical complications by identifying at-risk patients and providing a structured framework for clinical decision-making. The PICO 7 device is highlighted for its user-friendly features that support evidence-based practice.
Read more →SNNNew German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
Smith+Nephew has announced new expert consensus guidelines for the use of single-use negative pressure wound therapy (sNPWT) in Germany. These guidelines aim to improve clinical outcomes and address economic challenges associated with postoperative wound complications. The recommendations are based on a risk score to guide the targeted use of sNPWT in high-risk patients, promoting better healthcare resource management.
Read more →SNNSmith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew has announced the successful completion of the first clinical cases using its next-generation CORI XT Handheld Robotics Platform for knee and shoulder arthroplasty. The platform aims to enhance surgical accuracy while maintaining efficiency in established workflows. Surgeons have reported positive experiences with the technology, indicating its potential to improve patient outcomes.
Read more →SNNSmith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew has launched the next generation LEAF Patient Monitoring System in the US, aimed at preventing hospital-acquired pressure injuries (HAPIs). This innovative platform utilizes a wearable sensor to monitor patient mobility and provide real-time updates, enhancing care protocols. The system has shown to reduce HAPIs significantly and offers substantial cost savings for healthcare facilities.
Read more →SNNSmith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew is set to launch two new wound care products, ALLEVYN COMPLETE CARE Dressing and RENASYS EDGE tNPWT, at the EWMA Conference in May 2026. These innovations aim to enhance chronic wound management and improve patient outcomes. The products reflect the company's commitment to addressing the significant healthcare challenge posed by chronic wounds in Europe.
Read more →About Smith & Nephew SNATS, Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next SNN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime